Amy Liu brings over a decade of biopharma experience and is currently at Avidity Partners, an investment management firm focused on public and multi-stage private investments in innovative companies within the healthcare industry. Amy currently serves on the board of Prellis Biologics and GentiBio.

Prior to Avidity, Amy was a Principal at Mubadala Capital on the Ventures team and supported both the therapeutics investing strategy and the company creation efforts. She was closely involved with the builds of EpiBiologics, Light Horse Therapeutics, Tenvie Therapeutics, and Ollin Biosciences. Amy has previously held roles of increasing responsibility at BridgeBio across corporate and business development and also spent time as a sell side analyst at Evercore ISI covering small and mid cap biotech companies. Amy is a graduate of the Vagelos Life Science and Management Program and received her B.S. in Economics and B.A. in Biochemistry from the University of Pennsylvania.